LOVENOX Drug Patent Profile

When do Lovenox patents expire, and when can generic versions of Lovenox launch?

Lovenox is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in LOVENOX is enoxaparin sodium. There are thirteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the enoxaparin sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lovenox

A generic version of LOVENOX was approved as enoxaparin sodium by SANDOZ INC on November 28^th, 2011.

Summary for LOVENOX

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	17
Clinical Trials:	63
Drug Prices:	Drug price information for LOVENOX
What excipients (inactive ingredients) are in LOVENOX?	LOVENOX excipients list
DailyMed Link:	LOVENOX at DailyMed

See drug prices for LOVENOX

See drug sales revenues for LOVENOX

Recent Clinical Trials for LOVENOX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Fertility Center of Las Vegas	Phase 4
Regeneron Pharmaceuticals	Phase 2
Golisano Children's Hospital	Phase 2/Phase 3

See all LOVENOX clinical trials

Pharmacology for LOVENOX

Drug Class

Low Molecular Weight Heparin

US Patents and Regulatory Information for LOVENOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	LOVENOX	enoxaparin sodium	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	020164-009	Jan 23, 2003	AB	RX	Yes	No
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-005	Mar 27, 1998	AP	RX	Yes	Yes
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-003	Mar 27, 1998	AP	RX	Yes	No
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-007	Jun 2, 2000	AP	RX	Yes	No

Expired US Patents for LOVENOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	LOVENOX	enoxaparin sodium	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	020164-009	Jan 23, 2003
Sanofi Aventis Us	LOVENOX	enoxaparin sodium	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	020164-009	Jan 23, 2003
Sanofi Aventis Us	LOVENOX	enoxaparin sodium	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	020164-009	Jan 23, 2003

EU/EMA Drug Approvals for LOVENOX

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Techdow Pharma Netherlands B.V.	Inhixa	enoxaparin sodium	EMEA/H/C/004264Inhixa is indicated for adults for:Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery.Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL).Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism.Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA).Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL).Blood clot prevention in the extracorporeal circulation during haemodialysis.	Authorised	no	yes	no	2016-09-15
Pharmathen S.A.	Thorinane	enoxaparin sodium	EMEA/H/C/003795Thorinane is indicated for adults for:, , - Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery., , - Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL)., , - Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism., , - Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA)., , - Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL)., , - Blood clot prevention in the extracorporeal circulation during haemodialysis., , Prevention and treatment of various disorders related to blood clots in adults.,	Withdrawn	no	yes	no	2016-09-14

International Patents for LOVENOX

See the table below for patents covering LOVENOX around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	227417	PROCEDIMIENTO PARA LA OBTENCION DE MUCOPOLISACARIDOS QUE POSEEN ACTIVIDAD ANTI-XA(YIN-WESSLER)ELEVADA,CON UNA RELACION DE SU TITULO YIN-WISSLER A SU TITULO USP DE AL MENOS IGUAL A 2
Austria	17586
Austria	26450
Australia	540433

Last updated: June 20, 2026

Lovenox (enoxaparin) Market Dynamics and Financial Trajectory: Sales Trends, Competition, Patent/Exclusivity Timeline, and Generic/Biosimilar Risk

Lovenox (enoxaparin sodium) is a mature, large-volume branded anticoagulant with declining unit growth, pricing pressure from generics and authorized generics, and ongoing demand resilience driven by hospital use in DVT/PE prophylaxis and treatment settings. Financial trajectory is dominated by (1) U.S. and ex-U.S. market share shifts toward lower-cost enoxaparin products, (2) inventory and purchasing cycles in institutional channels, and (3) litigation and exclusivity outcomes tied to enoxaparin manufacturer approvals rather than “biologic-style” biosimilar dynamics.

How has Lovenox performed financially over time and what is the current market trajectory?

Sales trend drivers

Primary demand base

• Inpatient VTE prophylaxis after orthopedic surgery (hip/knee) and general surgery
• Treatment of DVT and PE, including initial outpatient continuation strategies in select settings
• Acute coronary syndromes (unstable angina/NSTEMI) and STEMI regimens

Key erosion forces

• Price compression after generic entry and authorized generic penetration
• Formulary decisions that favor lower-cost enoxaparin SKUs and contracting rebates
• Tender cycles that shift volume based on net pricing rather than brand-specific differentiation

Resilience factors

• Extensive clinical inertia and guideline entrenchment for LMWH dosing protocols
• Institutional preference for predictable supply and dosing familiarity
• Broader LMWH basket coverage by payer contracts (brand retained through preferred status when net price is competitive)

Where the money tends to sit

For large-volume anticoagulants, financial trajectory usually breaks into:

• U.S.: highest competitive intensity from multiple authorized generic and generic suppliers
• EU/UK: continued substitution but with fragmented tendering and product-level differences
• Rest of world: variability in regulatory approvals, local marketing strength, and tender controls

What competitive products most directly pressure Lovenox pricing and market share?

Direct substitutes

• Generic enoxaparin sodium (multiple manufacturers; tend to compete on wholesale price, rebate structure, and supply continuity)
• Authorized generics where applicable, typically priced below branded list price
• Alternative anticoagulant classes that can displace LMWH in parts of the pathway:
  • DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) for selected VTE indications and long-term treatment
  • Fondaparinux (where used)
  • UFH and other institutional protocols for specific populations

Competition in use-cases

• Perioperative prophylaxis: still largely LMWH-driven in many hospitals, but DOAC penetration exists for some elective settings
• Cancer-associated thrombosis: LMWH historically dominant; DOAC use varies by country, formulary, and bleeding-risk protocols
• Acute coronary syndromes: LMWH has durable use, but payer and guideline changes can shift dose selection

When does Lovenox lose exclusivity and what does that imply for generics?

Exclusivity is not a single date

Enoxaparin is a chemically derived anticoagulant with a long patent history. “Exclusivity loss” in practice is a patchwork:

• Originator compound-related patents (early expiry drives generic filings and approvals)
• Secondary patents (process, intermediates, specific formulations, and/or packaging) that can constrain certain “skinny” or manufacturing-specific entries
• Regulatory exclusivities (if any) that are distinct from patent exclusivity

Business implication

• Even after principal compound protection ends, the branded revenue curve typically continues a deceleration because:
  • competitors take time to scale supply
  • payers renegotiate contracts
  • hospitals switch based on tender cycles
  • pharmacy and nursing workflows adapt

What is the Orange Book status of Lovenox enoxaparin sodium in the U.S.?

The Orange Book listing is the operational map for:

• Which patents are listed for specific Lovenox NDA products
• Which expiration dates apply per strength and dosage form
• Which patents can be asserted in Paragraph IV litigation

Business-use interpretation

• When Orange Book lists multiple patents, the probability of “evergreen” barriers increases for certain generic manufacturers tied to listed method/process patents.
• When listings thin to a smaller set, “approval-then-entry” risk accelerates.

How does Lovenox patent estate strength compare with generic enoxaparin challengers?

What typically matters for LMWH estates

• Method-of-manufacture patents: can slow generic production transitions if a competitor needs a workaround
• Process and impurity-control patents: can affect whether a generic can meet specifications without infringing
• Packaging/presentation patents (less common than manufacturing/process but still relevant)

How challengers respond

Generic entrants typically choose:

• “Workaround-first” engineering to avoid listed claims
• Accelerated launch once key patents expire or are cleared through settlement

Financial impact

• Branded sales usually suffer a step-down when at least one major competitor is approved and contracts allow substitution at scale.

What patent litigation affects Lovenox and what are the settlement dynamics?

Typical litigation mechanics

• Paragraph IV ANDA challenges are aimed at one or more Orange Book-listed patents
• District court results or settlements can delay or remove certain launch dates for specific product configurations
• Settlements can allow “at-risk” launches for some labels while other labels remain delayed

Business implication of settlement patterns

• A settlement that preserves a narrow launch window for the generic can still produce a rapid revenue decline if it shifts price baselines in major purchasing accounts.
• A settlement that blocks key dosage strengths can preserve brand share for those strengths but not for overall therapy categories.

Is Lovenox riskier like a biosimilar product, or is it a traditional small-molecule generic story?

Lovenox is not a biologic product and does not face biosimilar pathways. Competitive risk is primarily:

• ANDA-based generic competition
• Authorized generic competition
• Patent/process barriers and litigation

Business implication

• The competitive “shock” tends to occur around approval and contract renegotiations rather than around biosimilar interchangeability milestones.

How do formulations, strengths, and delivery devices affect generic entry risk?

Dosage form and packaging

Lovenox is available in multiple:

• Strengths (e.g., prefilled syringes across standard dosing regimens)
• Packaging configurations (often important for hospital inventory)

Why device/packaging matters legally and commercially

• Generic approval can be label-specific. A competitor may launch only the strengths that are cleared.
• Hospitals can remain on a branded strength if supply continuity and nursing workflow are operationally embedded.

Financial impact

• Branded revenue is often “sticky” within particular dosing schedules until substitution is feasible at the account level.

How does Lovenox compete against DOACs (apixaban, rivaroxaban) and other anticoagulants?

Displacement risk by indication

• Long-term VTE treatment: DOACs can displace LMWH in many settings
• Cancer-associated thrombosis: DOAC use varies; LMWH remains a default in some payer pathways
• Orthopedic prophylaxis: DOAC options exist, but practice patterns vary by country and institutional preference

Revenue dynamics

Even if Lovenox retains a strong base, DOACs can reduce incremental growth and accelerate volume declines in some cohorts, shifting the branded trajectory from growth to maintenance.

What is the commercialization profile of enoxaparin: channel, contracting, and inventory effects?

Hospital procurement structure

• Annualized contracts with tender-based pricing
• Rebate and rebate-like mechanisms that determine net cost
• Inventory management that amplifies short-term price effects

Timing effects

• Generic introductions often cause a near-term price reset when supply is stable
• Branded manufacturers can sometimes slow declines through:
  • targeted account pricing
  • contract renewals
  • supply continuity assurances during ramp-up periods for competitors

What are the highest-value market segments for Lovenox and how are they shifting?

Top segments by prescribing behavior

• Orthopedic prophylaxis (high institutional volume)
• Medical prophylaxis in acutely ill patients (varies by hospital protocols)
• Acute coronary syndromes (protocol-driven)

Shift factors

• Guideline updates that promote alternative anticoagulants
• Payer formulary changes that reward lower-cost alternatives
• Safety and bleeding-risk stratification protocols influencing choice

Which countries outside the U.S. are most likely to see faster enoxaparin erosion?

Erosion typically accelerates where

• Generic approval and local tender mechanics enable rapid switching
• Multiple suppliers compete on net pricing
• Regulatory barriers to substitution are low

Erosion typically slows where

• Local manufacturing capacity is limited
• Import restrictions or supply constraints raise switching friction
• Institutional contracting favors established suppliers

How strong is Lovenox’s long-term revenue outlook given generic penetration risk?

Base-case pattern for mature anticoagulants

• Gradual revenue compression from pricing
• Intermittent share losses based on tender outcomes
• Stabilization if branded pricing remains competitive or if specific strengths remain protected

What would improve the outlook

• Contract wins at net-price parity
• Supply continuity advantages versus entrants
• Stronger-than-expected adherence in indications where LMWH remains standard of care

What would worsen the outlook

• Broader substitution across more strengths and hospitals
• DOAC displacement expanding into additional patient subsets
• Successful litigation outcomes that clear additional entry labels sooner

Key Takeaways

• Lovenox’s financial trajectory is driven less by platform innovation and more by generic and authorized generic pricing resets, hospital contracting cycles, and indication-level displacement by DOACs.
• The competitive risk profile is traditional ANDA generic erosion, not biosimilar interchangeability dynamics.
• Business outcomes turn on Orange Book patent coverage by strength and on litigation/settlement mechanics that affect which labels enter and when.
• Long-term revenue is best modeled as declining price with demand resilience, with step-down periods aligned to competitor launches and contract renegotiations.

FAQs

1. Which Lovenox strengths typically face the fastest generic substitution risk?
2. What role do Paragraph IV settlements play in timing of generic enoxaparin launches?
3. How do DOAC guideline changes affect Lovenox share in VTE treatment and prophylaxis?
4. Do manufacturing-process patents for enoxaparin materially delay generic entry beyond compound patent expiry?
5. How does hospital tender structure influence the magnitude and timing of Lovenox revenue erosion?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. FDA (accessed via Orange Book database).
2. FDA. Drug Competition Action Plans and ANDA/Orange Book framework materials. U.S. FDA.
3. FDA. Guidance for Industry: Abbreviated New Drug Applications. U.S. FDA.

DrugChatter Q&A for LOVENOX

Lovenox preservative free?
Lovenox preservative free discount?